Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs-Reference-Cited by-同舟云学术

Lysocin E Targeting Menaquinone in the Membrane of Mycobacterium tuberculosis Is a Promising Lead Compound for Antituberculosis Drugs

Published:2022-09-20 Issue:9 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Geberetsadik Geberemichal¹²^ORCID,Inaizumi Akane¹,Nishiyama Akihito¹,Yamaguchi Takehiro¹³,Hamamoto Hiroshi⁴,Panthee Suresh⁵⁶^ORCID,Tamaru Aki⁷,Hayatsu Manabu⁸,Mizutani Yusuke⁸⁹,Kaboso Shaban Amina¹,Hakamata Mariko¹¹⁰,Ilinov Aleksandr¹¹¹,Ozeki Yuriko¹,Tateishi Yoshitaka¹,Sekimizu Kazuhisa⁵,Matsumoto Sohkichi¹¹²^ORCID

Affiliation:

1. Bacteriology, Niigata University School of Medicine, Niigata, Japan

2. Department of Biology, Natural and Computational Sciences Faculty, Assosa University, Assosa, Ethiopia

3. Department of Bacteriology I, National Institute of Infectious Diseases, Tokyo, Japan

4. Institute of Medical Mycology, Teikyo University, Tokyo, Japan

5. Drug Discoveries by Silkworm Models, Faculty of Pharma-Science, Teikyo University, Tokyo, Japan

6. Department of Medical Pathogenesis and Immunology, College of Medicine, Texas A&M University, Bryan, Texas, USA

7. Department of Infectious Diseases, Osaka Prefectural Institute of Public Health, Osaka, Japan

8. Division of Microscopic Anatomy, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

9. Office of Institutional Research, Hokkaido University, Sapporo, Hokkaido, Japan

10. Department of Respiratory Medicine and Infectious Disease, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

11. Department of General Surgery, Krasnoyarsk State Medical University, Krasnoyarsk, Russia

12. Laboratory of Tuberculosis, Institute of Tropical Disease, Universitas Airlangga, Surabaya, East Java, Indonesia

Abstract

Tuberculosis remains a public health crisis and a health security threat. There is an urgent need to develop new antituberculosis drugs with novel modes of action to cure drug-resistant tuberculosis and shorten the chemotherapy period by sterilizing tissues infected with dormant bacteria.

Funder

Ministry of Education, Culture, Sports, Science and Technology

Japan Agency for Medical Research and Development

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.00171-22

Reference24 articles.

1. World Health Organization. 2021. Global tuberculosis report 2021. World Health Organization, Geneva, Switzerland. https://www.who.int/publications/i/item/9789240037021.

2. A Novel Small-Molecule Inhibitor of the Mycobacterium tuberculosis Demethylmenaquinone Methyltransferase MenG Is Bactericidal to Both Growing and Nutritionally Deprived Persister Cells

3. Challenging the Drug-Likeness Dogma for New Drug Discovery in Tuberculosis

4. World Health Organization. 2020. Global tuberculosis report 2020. World Health Organization, Geneva, Switzerland. https://www.who.int/publications/i/item/9789240013131.

5. Novel MenA Inhibitors Are Bactericidal against Mycobacterium tuberculosis and Synergize with Electron Transport Chain Inhibitors

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microbial-derived peptides with anti-mycobacterial potential;European Journal of Medicinal Chemistry;2024-10

2. Tackling Nontuberculous Mycobacteria by Repurposable Drugs and Potential Leads from Natural Products;Current Topics in Medicinal Chemistry;2024-06

3. Silkworm model of bacterial infection facilitates the identification of lysocin E, a potent, ultra-rapid bactericidal antibiotic;The Journal of Antibiotics;2024-05-21

4. Mycobacterial DNA-binding protein 1 is critical for BCG survival in stressful environments and simultaneously regulates gene expression;Scientific Reports;2023-08-29